BMC Research Notes





Bacillus anthracis gamma phage lysis among soil bacteria: an update on test specificity

Cari B. Kolton^{1*}, Nicole L. Podnecky^{1,2}, Sean V. Shadomy^{1,3,4}, Jay E. Gee¹ and Alex R. Hoffmaster¹

Abstract

Background: *Bacillus anthracis*, which causes anthrax in humans and animals, is enzootic in parts of the U.S. state of Texas where cases are typically reported in animals annually. The gamma phage lysis assay is a common diagnostic method for identification of *B. anthracis* and is based on the bacterium's susceptibility to lysis. This test has been shown to be 97% specific for *B. anthracis*, as a small number of strains of other *Bacillus* spp. are known to be susceptible. In this study, we evaluated the performance of a combination of *B. anthracis* diagnostic assays on 700 aerobic, spore-forming isolates recovered from soil collected in Texas. These assays include phenotypic descriptions, gamma phage susceptibility, and real-time polymerase chain reaction specific for *B. anthracis*. Gamma phage-susceptible isolates that were ruled out as *B. anthracis* were identified by 16S rRNA gene sequencing.

Findings: We identified 29 gamma phage-susceptible isolates. One was confirmed as *B. anthracis*, while the other 28 isolates were ruled out for *B. anthracis* by the other diagnostic tests. Using 16S rRNA gene sequencing results, we identified these isolates as members of the *B. cereus* group, *Bacillus* sp. (not within *B. cereus* group), *Lysinibacillus* sp., and *Solibacillus silvestris*. Based on these results, we report a specificity of 96% for gamma phage lysis as a diagnostic test for *B. anthracis*, and identified susceptible isolates outside the *Bacillus* genus.

Conclusions: In this study we found gamma phage susceptibility to be consistent with previously reported results. However, we identified non-*B. anthracis* environmental isolates (including isolates from genera other than *Bacil-lus*) that are susceptible to gamma phage lysis. To date, susceptibility to gamma phage lysis has not been reported in genera other than *Bacillus*. Though these isolates are not of clinical origin, description of unexpected positives is important, especially as new diagnostic assays for *B. anthracis* are being developed based on gamma phage lysis or gamma phage proteins.

Keywords: Bacillus anthracis, Anthrax, Gamma phage

Background

Bacillus anthracis, the cause of anthrax in humans and animals, is an endospore-forming bacterium that can persist in the environment for many years. In the U.S., *B. anthracis* infections in animals occur in states that are enzootic for the disease, such as Texas, North and South Dakota, and Minnesota [1–5]. Anthrax outbreaks

*Correspondence: fts3@cdc.gov

Full list of author information is available at the end of the article



have occurred annually in livestock and wild game in Texas for the past decade. Outbreaks pertinent to this study include an outbreak in a cattle herd in July 2007 on a ranch north of San Angelo, Texas, and an outbreak in horses on an adjacent ranch in August 2007 [6, 7].

Identification of *B. anthracis* is commonly based on colony morphology (including hemolysis), capsule production, detection of virulence plasmids (pXO1 and pXO2) by real-time PCR, and susceptibility to lysis by gamma phage [8–10]. The gamma phage assay is widely used as a diagnostic test for *B. anthracis* in many laboratories

© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/ publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

¹ Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA, USA

due to ease and low cost of use. Recently, several studies have used gamma phage binding and lytic activity as the basis for newer diagnostic assays, such as using engineered phage for bioluminescent detection [11-16]. The specificity and sensitivity of gamma phage has been previously documented, and although the specificity for *B. anthracis* is very high (97%), a small number of isolates of close relatives, including examples of *Bacillus cereus* and *Bacillus thuringiensis*, are susceptible [9, 17]. In this study, we evaluated the specificity of the gamma phage assay in conjunction with other diagnostic tests to screen 700 spore-forming Texas soil isolates for identification of *B. anthracis*.

Methods

Texas soil collection and processing

Core soil samples were collected in September 2007 from two sites in Texas in or near the municipalities of Schertz and San Angelo. Schertz was chosen due to the previous identification of pathogenic *B. cereus* isolates (two clinical, one environmental) harboring *B. anthracis* toxin and/or capsule genes that were associated with fatal pneumonias in metal workers from the area in 2003 [18]. San Angelo was chosen due to the recent anthrax outbreaks in cattle and horses mentioned above [6, 7]. Sterile 50 mL conical tubes were uncapped and twisted down into the soil to a depth of approximately 2.5–3.0 cm. The tubes containing the core samples were then re-capped and wrapped in parafilm. Samples were shipped at ambient temperature and subsequently stored at – 30 °C until processing.

Three samples were selected for testing (one from Schertz and two from San Angelo), and 2-3 bacterial extractions were performed on each sample. For each extraction, approximately 3.5 g of soil were transferred to a sterile 15 mL conical tube. The soil was saturated with phosphate-buffered saline containing 0.3% Tween 20 (PBST) and an additional 1.0 mL of PBST was added, then the sample was vortexed at high speed for 1-3 min. To select for spore-forming bacteria, the samples were heat shocked at 65 °C for 30 min and allowed to settle. The supernatant was transferred to a 2.0 mL screw-cap tube, and briefly centrifuged at 2000-3000 rpm. The following amounts were plated to produce 20-50 colonies/ plate: 100 µL of the undiluted supernatant was plated onto PLET (polymyxin, lysozyme, ethylenediaminetetraacetic acid, thallium acetate) agar plates, a selective medium for B. anthracis [19], while 100 µL aliquots of a 1:20 dilution were plated onto 10 trypticase soy agar plates containing 5% sheep blood (SBA). Both PLET and SBA plates were incubated overnight at 37 °C. Seven hundred random single colonies were picked and streaked to SBA for isolation. Isolates were then streaked onto sporulation medium (agar containing tryptone, peptone, yeast extract, and manganous chloride) and incubated at 30 °C for 5–7 days. Spores were harvested in 25% glycerol in deionized water and stored as spore suspensions at -70 °C.

Isolate screening and identification

Phenotypic characteristics, including hemolysis and colony morphology on SBA (see Additional file 1), and gamma phage susceptibility were recorded for all isolates. Gamma phage testing was performed as previously described [9], with susceptibility defined as any amount of lysis or reduced growth where gamma phage was applied. Cell lysates containing DNA were prepared as previously described [8], and were tested using the Laboratory Response Network's real-time PCR assay for detection of the B. anthracis chromosome, and of virulence plasmids pXO1 and pXO2 genes (pagA and capB, respectively) [8, 17]. For isolates exhibiting susceptibility to gamma phage lysis, the cell wall (CW) and capsule (CAP) direct fluorescent antibody (DFA) assays were also performed as previously described [10]. Gamma phagesusceptible isolates that were ruled-out for B. anthracis using the tests above were identified by 16S rRNA gene sequencing as previously described [20]. For isolates that produced readable sequences, the sequences were compared to published type strain sequences (when applicable) in NCBI's GenBank database using BLAST, using a sequence similarity of 99–100%. The 16s rRNA sequences of isolates 2008723338, 2008723339, 2008723400, 2008723423, 200872372 and 2008723476 were deposited in GenBank with Accession Numbers KT254134, KT254135, KT254136, KT254137, KT254138 and KT254139, respectively. Isolates identified as belonging to the B. cereus group were further typed by multi locus sequence typing (MLST), performed as previously described [21].

Table 1	Results of	gamma	phage su	sceptibility	v testina
---------	-------------------	-------	----------	--------------	-----------

	Final identifica	Totals	
	B. anthracis	Other spp.	
Gamma phage lysis			
Positive	1 ^b	28 ^c	29
Negative	O ^d	671 ^e	671
Totals	1	699	700


^a Final identification based on *B. anthracis* real-time PCR, 16S rRNA gene sequencing, and CW- and CAP-DFA

^b Number of true positives

^c Number of false positives

^d Number of false negatives

^e Number of true negatives



grouping (shown in bold) to a panel of related bacteria. Bootstrap values (based on 1000 replications) are given as percentages at branch nodes. Brevibacillus brevis is used as an outgroup for this analysis




Fig. 2 Relationships between *B. cereus* group member isolates of this study and select reference isolates using concatenated sequences from seven housekeeping alleles. Sequence types (STs) with previously identified gamma phage susceptible isolates are shown in bold, and isolates from this study with new STs are marked (asterisk). The tree was constructed using the neighbor joining method and percent bootstrap confidence levels were calculated using 1000 resamplings of the original data

Findings

Twenty-nine of the 700 isolates were susceptible to gamma phage lysis, with 20 exhibiting hemolysis on SBA and with variable colony morphologies (see Additional files 1 and 2). One isolate was identified as B. anthracis (PCR positive for all targets, nonhemolytic, gamma phage-susceptible, and positive by CW- and CAP-DFA assays). The other 28 isolates were negative for all three B. anthracis PCR markers, including virulence genes pagA and *capB*, and all were negative for the CW-DFA and CAP-DFA assays except for isolate 2008723634, which was weakly positive for the CW-DFA assay. Based on the combined results of these tests, 28 of the 29 gamma phage-susceptible isolates were ruled out as *B. anthracis*. We calculated the specificity of the gamma phage test as 96% by dividing the number of true negatives by the sum of the number of true negatives plus the number of false positives, multiplied by 100 (see Table 1). Twenty-five of these 28 isolates produced readable 16S rRNA gene sequences, and were identified as follows: six Lysinibacillus spp., one Bacillus sp., one Solibacillus silvestris, and 17 isolates could only be identified as "B. cereus group members" due to the inability to distinguish members of the B. cereus group based on 16S gene sequencing. Representative isolates from each group are shown in Fig. 1. The 16S sequence data was not analyzed for three isolates due to failure to amplify.

Multi locus sequence typing was performed on all of the 17 B. cereus group isolates, however, only eight isolates produced usable gene segments for all seven alleles. All eight isolates were different sequence types (ST), and therefore, not multiple isolations of a single clone. Seven of the eight isolates were new STs, and were compared with other previously identified gamma phage-susceptible B. cereus isolates, as well as other B. cereus-group STs (Fig. 2) [17, 21]. None of the eight *B. cereus* group isolates identified cluster with previously identified gamma phage-susceptible isolates (ST-129, ST-130, or ST-132), however six of the isolates from this study did cluster closely together (Fig. 2) [21]. The other two B. cereus group isolates (2008723644 and 2008723286) were identified as ST-502 or clustered nearest to ST-502, respectively.

In conclusion, the diagnostic tests used in this study showed high specificity (real-time PCR 100% and gamma phage 96%). Interestingly, despite reports of B. cereus isolates harboring pXO1 and pXO2 plasmids or some of their genes (pagA and capB), these markers were not detected in any of the 700 isolates, except for the single B. anthracis isolate [18, 22–24]. Though gamma phage susceptibility is considered specific for B. anthracis, rare false positives can occur due to the susceptibility of a few other species. To our knowledge, this is the first report of susceptible isolates outside the Bacillus genus. Though the isolates described in this study are of environmental origin rather than clinical, and are often thought of as contaminants in the clinical laboratory, most can be opportunistic pathogens [25]. Therefore, it is important to note their existence, especially when new diagnostic methods are being developed using gamma phage or gamma phage proteins for the detection of *B. anthracis* in clinical or environmental samples [11–16].

Additional files

Additional file 1: Table S1. Colony morphologies of gamma phagesusceptible isolates on SBA after overnight incubation at 37 °C.

Additional file 2: Table S2. Isolation, hemolysis, and identification results of gamma phage-susceptible isolates.

Abbreviations

PCR: polymerase chain reaction; PBST: phosphate-buffered saline containing 0.3% Tween 20; PLET: polymyxin, lysozyme, ethylenediaminetetraacetic acid, thallium acetate; SBA: trypticase soy agar plates containing 5% sheep blood; CW-DFA: cell wall direct fluorescent antibody; CAP-DFA: capsule direct fluorescent antibody; ST: sequence type.

Authors' contributions

ARH and SVS conceived and designed the study; SVS and CBK collected the samples; NLP and CBK performed the experiments and collected data; JEG analyzed the data; CBK wrote the manuscript; NLP, SVS, JEG, and ARH revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Author details

¹ Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA, USA. ² Present Address: Department of Pharmacy, Faculty of Health Sciences, UIT The Arctic University of Tromsø, Hansine Hansens veg 18, Tromsø, Norway. ³ Present Address: One Health Office, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. ⁴ Food and Agriculture Organization of the United Nations, Viale delle Terme di Caracalla, 00153 Rome, Italy.

Acknowledgements

This publication made use of the *Bacillus cereus* Multi Locus Sequence Typing website (http://pubmlst.org/bcereus/) developed by Keith Jolley and sited at the University of Oxford [26]. The development of this site has been funded by the Wellcome Trust.

The views expressed in this article are those of the authors and do not necessarily reflect the official position of the Centers for Disease Control and Prevention, nor the US government.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

16S ribosomal RNA gene sequences for the six isolates that produced readable sequences are available from GenBank under the Accessions KT254134, KT254135, KT254136, KT254137, KT254138, and KT254139. Phenotypic data and isolation and identification data for all gamma phage-susceptible isolates are provided in Additional files 1 and 2. The non-*B. anthracis* bacterial isolates described in this study are available from the Centers for Disease Control and Prevention by executing a Material Transfer Agreement.

Ethics approval and consent to participate

Funding

Not applicable.

Nicole L. Podnecky was supported by the Emerging Infectious Disease Fellowship Program administered by the Association of Public Health Laboratories and funded by the Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 27 October 2016 Accepted: 8 November 2017 Published online: 16 November 2017

References

- Blackburn JK, McNyset KM, Curtis A, Hugh-Jones ME. Modeling the geographic distribution of *Bacillus anthracis*, the causative agent of anthrax disease, for the contiguous United States using predictive ecological niche modeling. Am J Trop Med Hyg. 2007;77:1103–10.
- Mullins JC, Van Ert M, Hadfield T, Nikolich MP, Hugh-Jones ME, Blackburn JK. Spatio-temporal patterns of an anthrax outbreak in white-tailed deer, Odocoileus virginanus, and associated genetic diversity of Bacillus anthracis. BMC Ecol. 2015;15:23.
- CDC. Human anthrax associated with an epizootic among livestock— North Dakota, 2000. MMWR Morb Mortal Wkly Rep. 2001;50:677–80.
- Mongoh MN, Dyer NW, Stoltenow CL, Khaitsa ML. Risk factors associated with anthrax outbreak in animals in North Dakota, 2005: a retrospective case-control study. Public Health Rep. 2008;123:352–9.
- Blackburn JK, Goodin DG. Differentiation of springtime vegetation indices associated with summer anthrax epizootics in west Texas, USA, deer. J Wildl Dis. 2013;49:699–703.
- Anthrax, bovine, wildlife—USA (TX). ProMED-mail 2007; 13 Jul: 20070713.2246. http://www.promedmail.org.
- Anthrax, livestock, equine—USA (TX). ProMED-mail 2007; 15 Aug: 20070815.2661. http://www.promedmail.org.
- Hoffmaster AR, Meyer RF, Bowen MD, Marston CK, Weyant RS, Thurman K, Messenger SL, Minor EE, Winchell JM, Rassmussen MV, et al. Evaluation and validation of a real-time polymerase chain reaction assay for rapid identification of *Bacillus anthracis*. Emerg Infect Dis. 2002;8:1178–82.
- Abshire TG, Brown JE, Ezzell JW. Production and validation of the use of gamma phage for identification of *Bacillus anthracis*. J Clin Microbiol. 2005;43:4780–8.
- De BK, Bragg SL, Sanden GN, Wilson KE, Diem LA, Marston CK, Hoffmaster AR, Barnett GA, Weyant RS, Abshire TG, et al. A two-component direct fluorescent-antibody assay for rapid identification of *Bacillus anthracis*. Emerg Infect Dis. 2002;8:1060–5.
- Shabani A, Marquette CA, Mandeville R, Lawrence MF. Carbon microarrays for the direct impedimetric detection of *Bacillus anthracis* using gamma phages as probes. Analyst. 2013;138:1434–40.

- Sainathrao S, Mohan KV, Atreya C. Gamma-phage lysin PlyG sequencebased synthetic peptides coupled with Qdot-nanocrystals are useful for developing detection methods for *Bacillus anthracis* by using its surrogates, *B. anthracis*-Sterne and *B. cereus*-4342. BMC Biotechnol. 2009;9:67.
- Kikkawa HS, Ueda T, Suzuki S, Yasuda J. Characterization of the catalytic activity of the gamma-phage lysin, PlyG, specific for *Bacillus anthracis*. FEMS Microbiol Lett. 2008;286:236–40.
- Fujinami Y, Hirai Y, Sakai I, Yoshino M, Yasuda J. Sensitive detection of *Bacillus anthracis* using a binding protein originating from gamma-phage. Microbiol Immunol. 2007;51:163–9.
- Schofield DA, Westwater C. Phage-mediated bioluminescent detection of Bacillus anthracis. J Appl Microbiol. 2009;107:1468–78.
- Sharp NJ, Vandamm JP, Molineux IJ, Schofield DA. Rapid detection of Bacillus anthracis in complex food matrices using phage-mediated bioluminescence. J Food Prot. 2015;78:963–8.
- Marston CK, Gee JE, Popovic T, Hoffmaster AR. Molecular approaches to identify and differentiate *Bacillus anthracis* from phenotypically similar *Bacillus* species isolates. BMC Microbiol. 2006;6:22.
- Avashia SB, Riggins WS, Lindley C, Hoffmaster A, Drumgoole R, Nekomoto T, Jackson PJ, Hill KK, Williams K, Lehman L, et al. Fatal pneumonia among metalworkers due to inhalation exposure to *Bacillus cereus* containing *Bacillus anthracis* toxin genes. Clin Infect Dis. 2007;44:414–6.
- Knisely RF. Selective medium for *Bacillus anthracis*. J Bacteriol. 1966;92:784–6.

- 20. Gee JE, De BK, Levett PN, Whitney AM, Novak RT, Popovic T. Use of 16S rRNA gene sequencing for rapid confirmatory identification of *Brucella* isolates. J Clin Microbiol. 2004;42:3649–54.
- Hoffmaster AR, Novak RT, Marston CK, Gee JE, Helsel L, Pruckler JM, Wilkins PP. Genetic diversity of clinical isolates of *Bacillus cereus* using multilocus sequence typing. BMC Microbiol. 2008;8:191.
- Hoffmaster AR, Hill KK, Gee JE, Marston CK, De BK, Popovic T, Sue D, Wilkins PP, Avashia SB, Drumgoole R. Characterization of *Bacillus cereus* isolates associated with fatal pneumonias: strains are closely related to *Bacillus anthracis* and harbor *B. anthracis* virulence genes. J Clin Microbiol. 2006;44:3352–60.
- Hoffmaster AR, Ravel J, Rasko DA, Chapman GD, Chute MD, Marston CK, De BK, Sacchi CT, Fitzgerald C, Mayer LW, et al. Identification of anthrax toxin genes in a *Bacillus cereus* associated with an illness resembling inhalation anthrax. PNAS. 2004;101:8449–54.
- Klee SR, Ozel M, Appel B, Boesch C, Ellerbrok H, Jacob D, Holland G, Leendertz FH, Pauli G, Grunow R, Nattermann H. Characterization of *Bacillus anthracis*-like bacteria isolated from wild great apes from Cote d'Ivoire and Cameroon. J Bacteriol. 2006;188:5333–44.
- Wenzler E, Kamboj K, Balada-Llasat JM. Severe sepsis secondary to persistent Lysinibacillus sphaericus, Lysinibacillus fusiformis and Paenibacillus amylolyticus bacteremia. Int J Infect Dis. 2015;35:93–5.
- Jolley KA, Maiden MC. BIGSdb: scalable analysis of bacterial genome variation at the population level. BMC Bioinform. 2010;11:595.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Submit your manuscript at www.biomedcentral.com/submit

• Maximum visibility for your research

